PharmacoEconomics

, Volume 20, Issue 7, pp 475–484 | Cite as

A Model to Estimate the Cost Benefit of an Occupational Vaccination Programme for Influenza with Influvac® in the UK

Original Research Article

Abstract

Objectives: To model the economic impact of introducing an occupational vaccination programme for influenza with an inactivated influenza subunit vaccine (Influvac®) in the UK.

Design and setting: Using published sources, a decision tree was constructed which modelled the costs and benefits of introducing an influenza vaccine in a business in the UK from the perspective of an employer.

Study participants and interventions: The model considered the implementation of an occupational vaccination programme with Influvac® in a business employing 1000 normal healthy adults earning the national average wage in the UK. The model assumed that 95% of employees would be absent from work after contracting influenza for a mean of 5 days and that the level of productivity would be reduced by 60% for one day by 85% of sick employees returning to work.

Main outcome measures and results: The expected probability of an employee being absent from work following an influenza vaccination would be reduced from 5.7 to 1.8% when the incidence of influenza in the community is 6%.Accordingly, if all 1000 employees were vaccinated, a business would be expected to reduce absenteeism from work attributable to an influenza outbreak by 220 days. Moreover, the expected return on every pound invested by an employer would be £1.03, £3.09 and £5.15 (2000 values) when the annual incidence of influenza in the community is 2, 6 and 10%, respectively.

Conclusions: Implementation of an occupational vaccination programme with Influvac® would be expected to reduce the incidence of influenza among a workforce leading to less absenteeism from work and averted lost productivity. Even if the incidence of influenza was as low as 2% it may be a worthwhile investment for UK employers to vaccinate their employees with Influvac®.

References

  1. 1.
    Couch RB. Advances in influenza virus vaccine research. Ann N Y Acad Sci 1993; 685: 803–12PubMedCrossRefGoogle Scholar
  2. 2.
    Fleming DM. The contribution of influenza to combined acute respiratory infections, hospital admissions and deaths in winter. Commun Dis Public Health 2000; 3 (1): 32–8PubMedGoogle Scholar
  3. 3.
    Immunisation against infectious disease (green book). Norwich: The Stationary Office, 1996: 113–20Google Scholar
  4. 4.
    Ashley J, Smith T, Dunnell K. Deaths in Great Britain associated with influenza epidemic of 1989/90: population trends. OPCS. London. HM Stationary Office 1991; 65: 16–20Google Scholar
  5. 5.
    Levy E. French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics 1996; Suppl. 3: 62–6Google Scholar
  6. 6.
    Szucs TD. Influenza: the role of burden-of-illness research. Pharmacoeconomics 1999; 16 Suppl. 1: 27–32PubMedCrossRefGoogle Scholar
  7. 7.
    Postma MJ, Bos JM, van Gennep M, et al. Economic evaluation of influenza vaccination: assessment for the Netherlands. Pharmacoeconomics 1999; 16 Suppl. 1: 33–40PubMedCrossRefGoogle Scholar
  8. 8.
    Fedson DS. Evaluating the impact of influenza vaccination: a North American perspective. Pharmacoeconomics 1996; 9 Suppl. 3: 54–61PubMedCrossRefGoogle Scholar
  9. 9.
    Guest JF, Morris A. Community-acquired lower respiratory tract infections: the annual cost to the National Health Service. Br J Med Econ 1996; 10: 263–73Google Scholar
  10. 10.
    NHS Lung and Asthma Information Agency. Sickness absence from respiratory disease. London: Department of Public Health Sciences, St George’s Hospital Medical School, 1992Google Scholar
  11. 11.
    Govaert TME, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomised double- blind placebo-controlled trial. JAMA 1994; 272: 1661–5PubMedCrossRefGoogle Scholar
  12. 12.
    Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccination in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123: 519–27Google Scholar
  13. 13.
    Ahmed H, Nicholson K, Nguyen-Van-Tam J. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet 1995; 346: 591–5PubMedCrossRefGoogle Scholar
  14. 14.
    Ambrosch F, Fedson DS. Influenza vaccination in 29 countries: an update to 1997. Pharmacoeconomics 1999; 16 (1): 47–54PubMedCrossRefGoogle Scholar
  15. 15.
    Palache AM. Influenza immunisation. J Clin Res 1999; 2: 111–32Google Scholar
  16. 16.
    Fleming DM, Watson JM, Nicholas S, et al. Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989/90 using a general practice database. Epidemiol Infect 1995; 115: 581–9PubMedCrossRefGoogle Scholar
  17. 17.
    Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly people living in the community. N Engl J Med 1994; 22: 778–84CrossRefGoogle Scholar
  18. 18.
    Hak E, van Essen GA, Buskens E, et al. Is immunising all patients with chronic lung disease in the community against influenza cost effective?. Evidence from a general practice based clinical prospective cohort study in Utrecht, the Netherlands. J Epidemiol Community Health 1998; 52: 120–5PubMedCrossRefGoogle Scholar
  19. 19.
    Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working age population. J Occup Environ Med 1997; 39 (5): 408–14PubMedCrossRefGoogle Scholar
  20. 20.
    Fleming D, Charlton J, McCormick A. The population at risk in relation to influenza immunisation policy in England and Wales. Health Trends 1997; 29 (2): 42–7Google Scholar
  21. 21.
    Buxton Bridges C, Thompson WM, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomised controlled trial. JAMA. 2000; 284 (13): 1655–63CrossRefGoogle Scholar
  22. 22.
    Office for National Statistics. Quarterly projections of the New Earnings Survey. Labour market trends. Norwich: The Stationary Office, 2000 JunGoogle Scholar
  23. 23.
    Kumpulainen V, Makela M. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J Infect Dis 1997; 29 (2): 181–5PubMedCrossRefGoogle Scholar
  24. 24.
    Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. OccupMed (Lond) 1998; 48 (2): 85–90CrossRefGoogle Scholar
  25. 25.
    Demicheli V, Rivetti D, Deeks JJ, et al. Vaccines for preventing influenza in healthy adults (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3, 2000. Oxford: Update Software, 1997Google Scholar
  26. 26.
    Drummond MF, O’Brien BJ, Stoddart GL, et al. Cost benefit analysis. In: Drummond MF, O’Brien B, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1998: 205–31Google Scholar
  27. 27.
    Fleming DM, Ayres JG. Diagnosis and patterns of incidence of influenza, influenza-like illness and the common cold in general practice. J R Coll Gen Pract 1988; 38: 159–62PubMedGoogle Scholar
  28. 28.
    Sullivan KM. Health impact of influenza in the United States. Pharmacoeconomics 1996; 9 Suppl. 3: 26–33PubMedCrossRefGoogle Scholar
  29. 29.
    Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982; 4: 25–44PubMedGoogle Scholar
  30. 30.
    Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in healthcare professionals. A randomised trial. JAMA 1999; 281 (10): 908–13PubMedCrossRefGoogle Scholar
  31. 31.
    Koopmanschap MA, Rutten FH. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics 1993; 4 (6): 446–54PubMedCrossRefGoogle Scholar
  32. 32.
    de Koning J, Tuyl FA. The relation between labour time, production and employment. Rotterdam: Netherlands Economic Institute, 1984Google Scholar
  33. 33.
    Annual earnings survey 1997. London: The Stationary Office, 1997Google Scholar
  34. 34.
    Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 33: 889–93CrossRefGoogle Scholar
  35. 35.
    Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med 1997; 39 (5): 408–14PubMedCrossRefGoogle Scholar
  36. 36.
    Levy E. French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics 1996; 9 (3): 62–6PubMedCrossRefGoogle Scholar
  37. 37.
    Burckel E, Ashraf T, Galvao de Sousa Filho JP, et al. Economic impact of providing workplace influenza vaccination: a model and case study application at a Brazilian pharma-chemical company. Pharmacoeconomics 1999; 16: 563–76PubMedCrossRefGoogle Scholar
  38. 38.
    Yassi A, Kettner J, Hammond G, et al. Effectiveness and cost-benefit of an influenza vaccination program for healthcare workers. Can J Infect Dis 1991; 2: 101–8PubMedGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.CATALYST Health Economics ConsultantsNorthwood, MiddlesexUK

Personalised recommendations